{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:33:35Z","timestamp":1785252815726,"version":"3.55.0"},"reference-count":39,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s302215","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:58:45Z","timestamp":1619571525000},"page":"1725-1734","source":"Crossref","is-referenced-by-count":8,"title":["No Relevant Pharmacokinetic Drug\u2013Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-\u03b3 Agonist, in Healthy Subjects"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7868-1761","authenticated-orcid":true,"given":"Yu Kyong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-0531","authenticated-orcid":true,"given":"Jun Gi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-7555","authenticated-orcid":true,"given":"Min Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","volume":"368","author":"Yoon","year":"2006","journal-title":"Lancet"},{"key":"ref3","first-page":"142","volume":"38","author":"Barnes","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4093\/dmj.2019.0137","volume":"43","author":"Kim","year":"2019","journal-title":"Diabetes Metab J"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2020 abridged for primary care providers. Clin Diabetes. 2020;38(1):10\u201338. doi:10.2337\/cd20-as01","DOI":"10.2337\/cd20-as01"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/M20-2470","volume":"173","author":"Doyle-Delgado","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.5551\/jat.RV17042","volume":"27","author":"Sano","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12669\/pjms.35.1.100","volume":"35","author":"Rashid","year":"2019","journal-title":"Pak J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.21037\/atm.2019.05.82","volume":"7","author":"Scheen","year":"2019","journal-title":"Ann Transl Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1573399813666170816142351","volume":"14","author":"Minze","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref14","unstructured":"Ingelheim B. Jardiance\u00ae (Empagliflozin) Prescribing Information. CT USA: US Food and Drug Administration; 2016."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/157340309788970333","volume":"5","author":"Erdmann","year":"2009","journal-title":"Curr Cardiol Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.diabres.2019.04.006","volume":"151","author":"Kwon","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"ref17","unstructured":"Pharm CKD. Duvie Tab. (Lobeglitazone Sulfate) Prescribing Information. Republic of Korea: Ministry of Food and Drug Safety; 2013."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.clinthera.2011.09.023","volume":"33","author":"Kim","year":"2011","journal-title":"Clin Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40261-014-0197-y","volume":"34","author":"Park","year":"2014","journal-title":"Clin Drug Investig"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fendo.2018.00412","volume":"9","author":"Han","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drugs Evaluation Research. Guidance for Industry: Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Maryland: US Food and Drug Administration; 2020."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20132194. doi:10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"key":"ref23","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice E6 (R2). J Eur Med Agency. 2016."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.taap.2009.12.016","volume":"243","author":"Zhang","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref25","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Research CfDE. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Maryland: US Food and Drug Administration; 2001."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/VHRM.S993","volume":"4","author":"Chiarelli","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","volume":"17","author":"Bermudez","year":"2010","journal-title":"Am J Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1172\/JCI118860","volume":"98","author":"De Vos","year":"1996","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.2337\/diabetes.50.5.1158","volume":"50","author":"Oakes","year":"2001","journal-title":"Diabetes"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/jps.24378","volume":"104","author":"Lee","year":"2015","journal-title":"J Pharm Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","volume":"28","author":"Sarashina","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"Seman","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.2337\/dcS15-3007","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes Care"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.2337\/db13-0265","volume":"62","author":"Defronzo","year":"2013","journal-title":"Diabetes"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s13300-016-0174-y","volume":"7","author":"Baron","year":"2016","journal-title":"Diabetes Ther"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=68853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=68853","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:59:07Z","timestamp":1619571547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/no-relevant-pharmacokinetic-drugndashdrug-interaction-between-the-sodi-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2147\/dddt.s302215","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}